Home / Companies / Lfb Biomedicaments
Company family
Lfb Biomedicaments: medicine shortages
As of 2 Nov 2026, 3 Lfb Biomedicaments products have a reported shortage across 3 countries, covering 2 medicines.
Products short3rank #404 of 464
Medicines2active ingredients
Countries3/16
New in 90 days00 vs market pace
Typical duration15 monthsmedian so far
Manufacturing67%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changes| Date | Country | Medicine | Change |
|---|---|---|---|
| 2 Nov | BE | Hepatitis B Immunoglobulin Hepacaf 5 000 IU inf. sol. (pwdr. + solv.) i.v. 5000 IU + 100 ml | return pushed back 28 Feb → 15 Mar |
Open shortages over time
Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Von Willebrand Factor | 2 | 1 Aug 2025 | Other | 2/16 | |
| Hepatitis B Immunoglobulin | 1 | 1 Apr 2025 | Manufacturing problem | 2/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.